Hence, these results indicated that PID1 could accelerate Sorafenib-induced Raf-1 activation and facilitate the formation of Raf-1/BRAF heterodimerization, thereby blocking AKT activation via Raf-1-dependent pathway and leading to increased sensitivity of hepatoma cells to Sorafenib. The gene discussed is BRAF; the disease is hepatocellular carcinoma.